Does UnitedHealthcare Cover Dupixent?
The verdict
Covered on most plans
UnitedHealthcare covers Dupixent on the specialty tier with prior authorization via OptumRx and indication-specific step therapy, dispensed through OptumRx specialty pharmacy. UHC applies a combination-use restriction — concurrent use with JAK inhibitors or other biologics is not approved. Expect 25–33% coinsurance until the applicable out-of-pocket cap. Verify tier on your specific plan.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with UnitedHealthcare using your member ID.
Key facts
UHC/OptumRx blocks concurrent use of Dupixent with JAK inhibitors or other biologics — a distinctive restriction not universal across all insurers.
OptumRx / UHC coverage policy
About 79% of Medicare Part D recipients pay $0–$100/month for Dupixent; the 2026 Part D OOP cap of $2,100 protects all Medicare beneficiaries.
Sanofi/Regeneron Dupixent coverage data
Dupixent list price is approximately $3,993 per 2-pen carton (January 2025 estimate); average retail runs $5,350–$5,377/month — specialty-tier coinsurance and copay programs materially reduce what patients pay.
Sanofi/Regeneron published pricing
Medicare vs. commercial coverage
Whether UnitedHealthcare covers Dupixent depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Part D: covered on the specialty tier with PA and step therapy via OptumRx specialty pharmacy. Coinsurance is typically 25–33% after the deductible, capped at $2,100 for the full year under the 2026 Part D out-of-pocket limit. Approximately 79% of Medicare Part D recipients pay $0–$100/month per Sanofi/Regeneron. The manufacturer savings card is not available to Medicare beneficiaries. Dupixent is usually a Part D self-injected drug but can shift to Medicare Part B when clinic-administered.
Commercial / Employer
Group & marketplace plans
Commercial/Employer: covered on the specialty tier with PA via OptumRx and indication-specific step therapy. UHC applies a combination-use restriction — Dupixent will not be approved concurrently with JAK inhibitors or other biologics. OptumRx specialty-pharmacy dispensing is required. The Dupixent MyWay copay card can reduce commercial cost to as little as $0 for eligible commercially insured patients; it is not available for government-plan members. ACA/Individual plans also cover Dupixent with PA on the specialty tier where offered. Medicaid (UHC Community Plan) covers Dupixent for approved indications per state preferred-drug list with PA and step therapy at nominal cost-share.
The 5 boxes you must tick to get approved
Commercial plans that will consider Dupixent require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Dupixent actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
List price approximately $3,993 per carton of 2 injections (January 2025 estimate); average retail approximately $5,350–$5,377/month for two 300 mg/2 mL pens. Treat as estimate — verify with pharmacy.
List price with no coverage — before any manufacturer savings card.
With coverage
Commercial: typically 25–33% coinsurance after the deductible via OptumRx. Dupixent MyWay copay card can reduce cost to as little as $0 for eligible commercially insured patients. Medicare Part D: 25–33% coinsurance after deductible, capped at $2,100 for the year (2026 cap). Medicaid: nominal cost-share per state plan.
Typical monthly copay once prior authorization is approved.
Bridge program
Dupixent MyWay copay card: as little as $0 for eligible commercially insured patients. Not available to Medicare or Medicaid beneficiaries. Contact Sanofi/Regeneron or visit dupixent.com to enroll.
Reduced copay through the assistance program, where eligible.
All figures are estimates and vary by plan tier and pharmacy. Confirm your specific cost-share with UHC or OptumRx before filling.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Use the UHC formulary lookup tool
Go to myuhc.com or uhcprovider.com and use the drug search (formulary lookup) with your specific plan ID. Search 'dupilumab' or 'Dupixent' to see the current tier, PA requirements, and combination-use restrictions on your plan.
- 2
Contact OptumRx specialty pharmacy
Call OptumRx at the number on your UHC member ID card and ask about Dupixent specialty dispensing, prior-authorization requirements, and your estimated cost-share including any applicable copay-card eligibility.
- 3
Have your specialist initiate the prior authorization
Ask your allergist, dermatologist, or other treating specialist to submit the PA request through OptumRx. Gather your treatment history (topicals or prior biologics tried), diagnosis documentation, and confirm you are not currently on a JAK inhibitor or other biologic before they submit.
Options if UnitedHealthcare won't cover Dupixent
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Dupixent MyWay Patient Assistance
Sanofi/Regeneron offers the MyWay program for commercially insured patients and a separate patient-assistance program for uninsured or underinsured patients who meet income criteria. Visit dupixent.com for details.
Tralokinumab (Adbry)
Another IL-13 biologic approved for moderate-to-severe atopic dermatitis. May be preferred on certain plans; check your OptumRx formulary for tier and step-therapy requirements.
JAK inhibitors (upadacitinib, abrocitinib)
Oral JAK inhibitors are approved for atopic dermatitis and may be on a lower formulary tier. Because UHC prohibits concurrent use with Dupixent, your prescriber may need to choose between Dupixent and a JAK inhibitor — not combine them.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
Yes. UHC/OptumRx requires indication-specific step therapy. For atopic dermatitis, you typically need a documented trial of prescription-strength topical treatments. For asthma, you generally need a documented trial of another add-on biologic such as Xolair, Tezspire, or Nucala. Step-therapy requirements vary by indication; your specialist must document the prior treatment history in the PA submission.
No. UHC applies a combination-use restriction that prohibits concurrent use of Dupixent with JAK inhibitors (such as upadacitinib or abrocitinib) or other biologics. If you are currently on one of those agents, you and your prescriber will need to decide which treatment path to pursue before a Dupixent prior authorization can be approved. This is a UHC-specific policy; verify your plan details.
On Medicare Part D, Dupixent coinsurance is typically 25–33% after the deductible. Per Sanofi/Regeneron, about 79% of Medicare Part D recipients pay $0–$100/month; the 2026 Part D out-of-pocket cap of $2,100 limits your total annual drug cost. The Dupixent MyWay copay card is not available to Medicare beneficiaries. Confirm your plan-specific cost with OptumRx.
Yes, for eligible commercially insured patients the Dupixent MyWay copay card can reduce out-of-pocket cost to as little as $0. It is not available to Medicare, Medicaid, or other government-plan members. Enroll at dupixent.com. Even with the card, the drug must be dispensed through OptumRx specialty pharmacy and must meet PA requirements.
Yes, under certain conditions. Dupixent is usually a Part D self-injected specialty drug, but when it is administered in a clinical setting by a healthcare provider, it can be covered under Medicare Part B (the medical benefit) instead of Part D. This affects your cost-share calculation — Part B uses 20% coinsurance after the Part B deductible rather than the Part D specialty-tier coinsurance and OOP cap. Confirm with your UHC plan and treating provider.
Related Articles
Does Aetna Cover Vyvanse? 2026 CVS Caremark Formulary
Aetna covers Vyvanse via CVS Caremark — generic lisdexamfetamine preferred, brand non-preferred. 70 mg/day QL per Policy 5.60.024; age-22 PA required.
Read moreDoes Aetna Cover Prolia? CVS Caremark Medical Benefit | Curex
Aetna covers Prolia under the medical benefit with PA — a q6-month clinic injection, not Part D. Jubbonti biosimilar now preferred on CVS Caremark.
Read moreDoes Anthem Cover Adderall? 2026 Coverage Guide | Curex
Anthem covers Adderall through CarelonRx — generic preferred, brand non-preferred. Step therapy may apply on some plans. Verify your Anthem plan.
Read moreDoes Anthem Cover Contrave? 2026 Brand Coverage Guide | Curex
Anthem covers Contrave only if your plan has a weight-loss benefit. Many plans carve it out. CurAccess ~$99/mo is often the fastest path.
Read moreDoes Aetna Cover Contrave? 2026 CVS Caremark Guide | Curex
Aetna (CVS Caremark) often excludes Contrave under AOM carve-outs. Where covered, CVS BMI prior auth applies. Medicare bars it by law. CurAccess ~$99/mo.
Read moreDoes Aetna Cover Forteo? 2026 Coverage Guide
Aetna (CVS) often excludes brand Forteo in favor of generic teriparatide or Bonsity. Teriparatide is covered with PA and bisphosphonate step therapy. 2026.
Read moreThis content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with UnitedHealthcare before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation.